Ascend Capital’s Novavax NVAX Stock Holding History

Ascend Capital’s Portfolio NVAX Stock Details NVAX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2013 Q4	–	Sell	-12,992	Closed	-$819K	–	217
2013 Q3	$819K	Buy	+12,992	New	+$732K	0.03%	190

Other funds holding NVAX

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

HealthCor Management New York $109M AUM 10.64% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Ascend Capital's NVAX Position: Q4 2013 in Review

Ascend Capital sold out of Novavax (NVAX) in Q4 2013, closing a stake of 12,992 shares — an estimated $819K sold.

Ascend Capital first reported a position in NVAX in Q3 2013 and held it in 1 quarter. The position peaked at $819K in Q3 2013. 129 funds tracked by Wall St. Rank hold NVAX as of Q4 2013.

Ascend Capital reported no remaining Novavax position as of Q4 2013 after selling out during the quarter.
Ascend Capital sold 12,992 Novavax shares in Q4 2013, an estimated $819K.
Ascend Capital first reported a position in Novavax in Q3 2013 and held it in 1 quarter.
Ascend Capital's Novavax position peaked at $819K in Q3 2013.
129 funds tracked by Wall St. Rank held Novavax as of Q4 2013.

Based on Ascend Capital's 13F filing for Q4 2013, filed 14 Feb 2014.